Taiji Group released its 2026 interim report. First-half operating revenue was 5.085 billion yuan, down 10.1 percent year on year. Net profit attributable to the parent company was 87.86 million yuan, down 36.7 percent. Net profit attributable to the parent company after deducting non-recurring items was 40.18 million yuan, down 66.4 percent. Net operating cash flow was negative 222 million yuan, down 292.9 percent year on year. In the second quarter, operating revenue was 2.56 billion yuan, down 9.7 percent year on year. Net profit attributable to the parent company was 22.24 million yuan, down 65.4 percent. Net profit attributable to the parent company after deducting non-recurring items was 1.61 million yuan, down 95.9 percent. The company said the revenue decline was mainly affected by centralized procurement policies. Sales of some anti-infective drugs declined, and some respiratory system drugs were affected by an overall drop in sales of cough and cold products. The profit decline was mainly due to stronger market promotion activities and higher selling expenses. The decline in net operating cash flow was mainly due to higher payments for goods due during the period and increased operating expenditures. By segment, pharmaceutical industry sales revenue was 2.585 billion yuan, down 9.04 percent year on year. Pharmaceutical distribution sales revenue was 3.07 billion yuan, down 8.96 percent. The traditional Chinese medicine resources segment recorded sales revenue of 553 million yuan, up 12.19 percent. International business and other sales revenue was 53 million yuan, down 44.76 percent.
Chongqing Taiji Industry Group Co LtdFirst-half revenue, profit, and cash flow all declined significantly.
